Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2019 to May 2024
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and
development-focused biotechnology company dedicated to creating small
molecule drugs in the infectious disease field, today announced that 25
abstracts reporting the results of hepatitis C virus (HCV) treatment
regimens containing ABT-450, Enanta’s lead protease inhibitor, or
ABT-493, Enanta’s next-generation protease inhibitor, have been accepted
for presentation at The Liver Meeting, the Annual Meeting of the
American Association for the Study of Liver Diseases (AASLD), being held
November 7-11, 2014 in Boston, MA.
ABT-450 and ABT-493 are protease inhibitors identified within the
ongoing Enanta-AbbVie collaboration.
Abstracts will be presented highlighting results from AbbVie’s
investigational treatment regimen combining three direct-acting
antivirals (ABT-450/ritonavir, ombitasvir (formerly ABT-267) and
dasabuvir, formerly ABT-333) with or without ribavirin (RBV) in patients
with genotype 1 (GT1) chronic HCV infection. These abstracts include a
phase 2/3 study in patients co-infected with human immunodeficiency
virus type-1 (HIV-1) (TURQUOISE-I) and a phase 2 study in liver
transplant recipients without cirrhosis (CORAL-I).
Additionally, phase 2 data will be presented from investigational
studies evaluating the combination of ABT-450/ritonavir and ombitasvir
with or without RBV in genotype 4 (GT4) patients (PEARL-I). AbbVie will
also be presenting data from its two next-generation HCV compounds,
ABT-493 and ABT-530. Results from these studies support the ongoing
phase 2b combination studies in patients with HCV.
Abstracts can now be viewed at the AASLD website at www.aasld.org.
Poster and oral presentations reporting regimens containing ABT-450 and
ABT-493 are listed below:
Oral Presentations:November 9, 2014, 5:15 - 5:30 p.m. ET
-
#81. TURQUOISE-II: Regimens of ABT-450/r/Ombitasvir and Dasabuvir
With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected
Patients with Cirrhosis, Regardless of Baseline CharacteristicsM.W.
Fried; X. Forns; N. Reau; H. Wedemeyer; M.L. Shiffman; A. Castro; D.J.
Mutimer; S.S. Lee; R. Trinh; S.S. Lovell; L. Canizaro; M. Pedrosa; T.
Berg
November 9, 2014, 5:45 - 6:00 p.m. ET
-
#83. Integrated Efficacy Analysis of Four Phase 3 Studies in HCV
Genotype 1a-Infected Patients Treated with ABT-450/r/Ombitasvir and
Dasabuvir With or Without RibavirinG.T. Everson; G.
Dusheiko; E. Coakley; S.D. Shafran; F. Zoulim; M. Diago; B. Freilich;
R. Ravinuthala; S. Norris; J.J. Xiong; R. Trinh; T. Baykal; Y. Luo;
M.S. Sulkowski
November 11, 2014, 9:15 - 9:30 a.m. ET
-
#198. High Sustained Virologic Response Rates in Liver Transplant
Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-
450/r/Ombitasvir+Dasabuvir Plus RibavirinP.S. Mantry; P.Y.
Kwo; E. Coakley; H.S. Te; H.E. Vargas; R.S. Brown; F.D. Gordon; J.
Levitsky;N. Terrault; J.R. Burton; W. Xie; C. Setze; P. Badri;
R.A. Vilchez; X. Forns
November 11, 2014, 12:15 - 12:30 p.m. ET
-
#227. Epigenetic Analysis of the IFNλ3 Gene Identifies a Novel
Marker for Response to Therapy in HCV-infected SubjectsJeffrey
F. Waring; Emily Dumas; Eoin Coakley; Daniel E. Cohen; Kenneth B.
Idler; Ujjwal Das; Thomas Podsadecki; Sandeep Dutta
November 11, 2014, 12:00 - 12:15 p.m. ET
-
#238. The Pharmacokinetics and Safety of the Direct Acting
Antiviral Regimen of ABT-450/r, Ombitasvir with/without Dasabuvir in
Subjects with Mild, Moderate and Severe Renal Impairment Compared to
Subjects with Normal Renal FunctionA. Khatri; S. Dutta; T.C.
Marbury; R.A. Preston; L. Rodrigues-Jr; H. Wang; W. Awni; R. Menon
ABT-493-Related Poster Presentations:November 11, 2014,
8:00 a.m. - 12:00 p.m. ET:
-
#1946. A Next Generation HCV DAA Combination: Potent, Pangenotypic
Inhibitors ABT-493 and ABT-530 with High Barriers to ResistanceT.
Ng; T. Pilot-Matias; L. Lu; T. Reisch; T. Dekhtyar; P. Krishnan; J.
Beyer; R. Tripathi; R.B. Pithawalla; A. Asatryan; A.L. Campbell; J.
Kort; C. Collins
-
#1956. Potent Antiviral Activity of ABT-493 and ABT-530 With 3-Day
Monotherapy in Patients With and Without Compensated Cirrhosis With
Hepatitis C Virus (HCV) Genotype 1 InfectionE. Lawitz; W.D.
O'Riordan; B.L. Freilich; T.D. Box; J. Overcash; W. Liu; A.L.
Campbell; C. Lin; A Asatryan; J. Kort
-
#1986. Pharmacokinetics and Safety of Pan-Genotypic, Direct Acting
Protease Inhibitor, ABT-493, and NS5A Inhibitor, ABT-530, Following 3
day Monotherapy in HCV Genotype-1 Infected Subjects with or without
Compensated CirrhosisChih-Wei Lin; Wei Liu; Armen Asatryan;
Andrew L. Campbell; Sandeep Dutta
ABT-450-Related Poster Presentations:November 11, 2014,
8:00 a.m. - 12:00 p.m. ET:
-
#1928. Interferon-Free Regimens of Ombitasvir and ABT-450/r With or
Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I
Study ResultsS. Pol; K. Reddy; T. Baykal; C. Hezode; T.
Hassanein; P. Marcellin; M. Berenguer; K.M. Fleischer-Stepniewska; C.
Hall; C. Collins; R.A. Vilchez
-
#1931. SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients
Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without
RibavirinM. Colombo; O. Weiland; D.E. Cohen; J.J. DuFour; H.
Reynaert; M. Diago; E. Villa; A. Streinu-Cercel; W. Xie; T. Baykal; J.
Enejosa; E. Coakley; R. Trinh; T. Podsadecki
-
#1933. PEARL-IV Trial: Subgroup Analysis of Genotype 1a-Infected
Patients Treated With ABT-450/r/Ombitasvir With Dasabuvir With or
Without RibavirinD. Bernstein; Y. Luo; J.P. Lalezari; D.L.
Wyles; W. King; N. Tsai; M.N. Davis; T.E. Sepe; J. Fessel; M. King; T.
Podsadecki; C. Cooper
-
#1934. SVR12 Rate of 95.7% in 209 HCV Genotype 1-Infected Null
Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or
Without RibavirinI.M. Jacobson; J.J. DuFour; J. Enejosa;
R.J. de Knegt; P. Ferenci; H. Reynaert; A.M. Di Bisceglie; L. Larsen;
T. Baykal; L. Rodrigues-Jr; T. Podsadecki; D.M. Jensen; F. Poordad
-
#1936. Pooled analysis of resistance in patients treated with
ombitasvir/ABT- 450/r and dasabuvir with or without ribavirin in Phase
2 and Phase 3 clinical trialsP. Krishnan; R. Tripathi; G.
Schnell; T. Reisch; J. Beyer; M. Irvin; W. Xie; L. Larsen; T.
Podsadecki; T. Pilot-Matias; C. Collins
-
#1938. ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin
in HCV Genotype 1-infected Patients Receiving Stable Opioid
Substitution Treatment: Pooled Analysis of Efficacy and Safety in
Phase 2 and Phase 3 TrialsM. Puoti; C. Cooper; M.S.
Sulkowski; G.R. Foster; T. Berg; E. Villa; F. Rodriguez-Perez; V.
Rustgi; D.L. Wyles; M. King; B.H. McGovern; H. Wedemeyer
-
#1939. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Coinfected Patients
Treated with ABT-450/r/Ombitasvir, Dasabuvir and RibavirinD.L.
Wyles; M.S. Sulkowski; J.J. Eron; R. Trinh; J. Lalezari; J. Slim; J.C.
Gathe; C.C. Wang; R. Elion; F. Bredeek; R.O. Brennan; G. Blick; A.
Khatri; K. Gibbons; Y. Hu; L. Fredrick; T. Pilot-Matias; B. Da
Silva-Tillmann; B.H. McGovern; A.L. Campbell; T. Podsadecki
-
#1950. Time to Viral Suppression is Not Related to Achievement of
SVR12 in HCV GT1-infected Patients Treated with ABT-450/r/Ombitasvir
and Dasabuvir With or Without RibavirinM.S. Sulkowski; M.W.
Fried; R. Ozaras; V. Isakov; D.L. Wyles; P. Ferenci; J.J. Feld ; F.
Calinas; M. Gschwantler; M. King; T. Baykal; E.J. Gane
-
#1951. Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without
Ribavirin in HCV Genotype 1-infected Patients: Results From Phase 2
and Phase 3 TrialsM.W. Fried; A.M. Di Bisceglie; J.M.
Vierling; E.J. Gane; F. Nevens; S.I. Strasser; O. Weiland; S. Rugina;
S.S. Lovell; B. Da Silva-Tillmann; N. Shulman; N. Tsai; D.R. Nelson
-
#1953. Adherence to Prescribed Doses of ABT-450/r/Ombitasvir,
Dasabuvir, and Ribavirin in the Phase 3 PEARL-II, PEARL-III, and
PEARL-IV TrialsD. Bernstein; R.T. Marinho; D.E. Cohen; F.
Bredeek; F. Schneider; G.P. Norkrans; M.G. Curescu; M. Bennett; M.
Maevskaya; J. Fessel; W. Xie; Y. Luo; J. Enejosa
-
#1954. Identification and treatment of multiple subtypes of HCV
genotype 4 in the PEARL-I study with ombitasvir and ABT-450/r ±
ribavirinG.Schnell; R. Tripathi; J. Beyer; T. Reisch; P.
Krishnan; T. Baykal; C. Hall; R.A. Vilchez; T. Pilot-Matias; C. Collins
-
#1957. Pharmacokinetics of Cyclosporine and Tacrolimus, Following
Co-administration with the Direct Acting Antiviral Combination, ABT-
450/r, Ombitasvir and Dasabuvir, in Liver Transplant Patients with
Genotype-1 HCV InfectionP. Badri; A. Parikh; E. Coakley; B.
Ding; W. Awni; S. Dutta; R. Menon
-
#1961. Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without
Ribavirin in HCV Genotype 1-infected Patients: Results From PEARL II,
PEARL III, and PEARL IVJ.P. Lalezari; R. Pruitt; Y. Luo;
R.J. Aspinall; G.B. Gaeta; I. Olszok; W. King; S. Gurel; Y. Hu; J.
Enejosa;D.E. Cohen; N. Shulman; V.A. Luketic
-
#1962. TURQUOISE-II: Trends in Liver Fibrosis Testing, Hepatic
Synthetic Function, and Platelet Counts at Baseline and 12 Weeks After
Treatment With ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin in
HCV Genotype 1-Infected Patients with CirrhosisM.L.
Shiffman; K.V. Kowdley; S. Zeuzem; D.J. Mutimer; M. Bourlière; T.
Berg; S.S. Lee;S.S. Lovell; L. Canizaro; R. Trinh; G. Neff; P.Y. Kwo
-
#1968. Efficacy by Race or Geographic Region in HCV Genotype
1-infected Patients Treated with ABT-450/ritonavir/Ombitasvir and
Dasabuvir With or Without RibavirinJ.M. Vierling; M. Puoti;
D. Bernstein; N. Tsai; O. Weiland; M. Romero Gómez; F.A. Caruntu; J.J.
DuFour; F. Calinas; L. Larsen; F. Tatsch; P. Andreone
-
#1969. Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without
Ribavirin in HCV Genotype 1-infected Patients ≥65 Years of Age:
Results From Phase 2 and 3 TrialsS.L. Flamm; E.J. Gane; J.J.
DuFour; V. Rustgi; V.G. Bain; D.H. Crawford; P. Andreone; T.
Hassanein; W.W. Mazur; S.S. Lovell; B. Da Silva-Tillmann; N. Shulman;
M. Puoti; T.D. Box; I.M. Jacobson
-
#1972. ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin
in HCV Genotype 1-infected Patients with History of Depression or
Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3
TrialsD.R. Nelson; K. Reddy; A.M. Di Bisceglie; P. Ferenci;
D.H. Crawford; R.E. Stauber; A.A. Yakovlev; V. de Ledinghen; H.
Hinrichsen; D. Bernstein; R.J. de Knegt; T. Hassanein; S. Norris; J.J.
Xiong; B.H. McGovern; K. Agarwal
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs in the
infectious disease field. Enanta is discovering, and in some cases
developing, novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of the direct acting
antiviral (DAA) inhibitor classes – protease (partnered with AbbVie),
NS5A and nucleotide polymerase – as well as a host-targeted antiviral
(HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta
has created a new class of antibiotics, called Bicyclolides, for the
treatment of multi-drug resistant bacteria, with a focus on developing
an intravenous and oral treatment for hospital and community MRSA
(methicillin-resistant Staphylococcus aureus) infections.
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including with
respect to AbbVie’s plans for announcing additional data regarding
ABT-450 and ABT-493. Statements that are not historical facts are based
on our management’s current expectations, estimates, forecasts and
projections about our business and the industry in which we operate and
our management’s beliefs and assumptions. The statements contained in
this release are not guarantees of future performance and involve
certain risks, uncertainties and assumptions, which are difficult to
predict. Therefore, actual outcomes and results may differ materially
from what is expressed in such forward-looking statements. Important
factors that may affect actual results include the the actions of AbbVie
(our collaborator on ABT-450 and ABT-493), regulatory actions affecting
clinical development of ABT-450 and clinical development of competitive
product candidates and clinical development of ABT-493. Enanta cautions
investors not to place undue reliance on the forward-looking statements
contained in this release. These statements speak only as of the date of
this release, and Enanta undertakes no obligation to update or revise
these statements, except as may be required by law.
Investor ContactEnanta Pharmaceuticals, Inc.Carol
Miceli, 617-607-0710cmiceli@enanta.comorMedia
ContactMacDougall Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.com